Disease · MONDO_0018078

soft tissue sarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. soft tissue sarcoma. Diseases, record MONDO_0018078. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018078

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: soft tissue sarcoma; Open Targets
Open Targets ID: MONDO_0018078; Open Targets
Other names: connective tissue sarcoma, malignant mesenchymal tumor, malignant mesenchymal tumour, malignant soft tissue tumor, non-Rhabdo. soft tissue sarcoma, sarcoma of soft tissue, sarcoma of the soft tissue, soft part sarcoma; Open Targets
Disease Ontology: DOID:0070663; Disease Ontology
NCI Thesaurus: C9306; NCI Thesaurus
Orphanet: ORPHA:3394; Orphanet
Highest stage of its drugs: Approval, for 3 of its 233 drugs, from ClinicalTrials.gov, PMDA and TTD; Open Targets

Drugs233

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRABECTEDIN	CHEMBL450449	Small molecule	Approval	PMDA	31	30	30	Drugs and targets
OLARATUMAB	CHEMBL1743049	Antibody	Approval	ClinicalTrials.gov and TTD	13	12	12	Drugs and targets
PAZOPANIB HYDROCHLORIDE	CHEMBL1201733	Small molecule	Approval	PMDA	4	3	3	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	80	80	80	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 3	ClinicalTrials.gov	53	53	53	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	36	36	36	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 3	ClinicalTrials.gov	28	28	28	Drugs and targets
PAZOPANIB	CHEMBL477772	Small molecule	Phase 3	ClinicalTrials.gov	24	24	24	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	21	21	21	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets

1 to 10 of 233

See all 233 drugs

Targets242

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	22	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	17	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	16	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	14	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
PDCD1	Programmed cell death protein 1	13	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	12	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
TUBA1A	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	12	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets

1 to 10 of 242

See all 242 targets

Trials424

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02451943	A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma	Phase 3	509	2019-12-17	Soft Tissue Sarcoma	DOXORUBICIN, OLARATUMAB	Its record names the disease	ClinicalTrials.gov
NCT02049905	Phase 3 Study to Treat Patients With Soft Tissue Sarcomas	Phase 3	433	2024-06-13	Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma	ALDOXORUBICIN	Its record names the disease	ClinicalTrials.gov
NCT00753688	Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy	Phase 3	369	2011-12-21	Sarcoma, Soft Tissue	PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT02659020	A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma	Phase 1/2	310	2021-10-11	Soft Tissue Sarcoma	DOCETAXEL, GEMCITABINE, OLARATUMAB	Its record names the disease	ClinicalTrials.gov
NCT01574716	Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation	Phase 2	209	2019-08-21	Metastatic Soft Tissue Sarcoma	DOCETAXEL, GEMCITABINE, ONTUXIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01016015	Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma	Phase 2	178	2015-07-30	Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma	CIXUTUMUMAB, TEMSIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT02357810	Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas	Phase 2	178	2020-08-10	Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma	PAZOPANIB HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00297258	Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma	Phase 2	148	2010-01-06	Sarcoma, Soft Tissue	PAZOPANIB	Its record names the disease	ClinicalTrials.gov
NCT01185964	A Study of Olaratumab in Soft Tissue Sarcoma	Phase 1/2	148	2017-04-14	Sarcoma, Soft Tissue	DOXORUBICIN, OLARATUMAB	Its record names the disease	ClinicalTrials.gov
NCT02301039	SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas	Phase 2	144	2020-09-29	Soft Tissue Sarcoma, Bone Sarcoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 424

See all 424 trials

Comparisons in its trials59

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Doxorubicin + Olaratumab vs Doxorubicin + Placebo: deaths from any cause	170 of 257	158 of 249	506	NCT02451943	Trial comparisons
Doxorubicin + Olaratumab vs Doxorubicin + Placebo: serious adverse events	105 of 257	89 of 249	506	NCT02451943	Trial comparisons
Aldoxorubicin vs Investigator's Choice of Treatment: deaths from any cause	148 of 213	131 of 207	420	NCT02049905	Trial comparisons
Aldoxorubicin vs Investigator's Choice of Treatment: serious adverse events	91 of 213	68 of 207	420	NCT02049905	Trial comparisons
Pazopanib vs Placebo: serious adverse events	99 of 240	29 of 123	363	NCT00753688	Trial comparisons
Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel vs Part 2: Placebo + Gemcitabine/Docetaxel: Part 2: Number of Participants Who Had Relationship Between MORAb-004 Exposures and Biomarker Levels	0 of 139	0 of 70	209	NCT01574716	Trial comparisons
PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: deaths from any cause	9 of 76	18 of 76	152	NCT03365791	Trial comparisons
PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: serious adverse events	31 of 76	4 of 76	152	NCT03365791	Trial comparisons
Doxorubicin vs INNO-206: Number of Participants With Treatment-related Toxicities (Adverse Events)	29 of 40	75 of 83	123	NCT01514188	Trial comparisons
Doxorubicin vs INNO-206: deaths from any cause	26 of 40	40 of 83	123	NCT01514188	Trial comparisons

1 to 10 of 59

See all 59 comparisons in its trials

Papers from its trials197

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39894354	RESULT	1	PubMed
36303228	RESULT	1	PubMed
35618839	RESULT	1	PubMed
34740331	RESULT	1	PubMed
33932507	RESULT	1	PubMed
32713836	RESULT	1	PubMed
31595663	RESULT	1	PubMed
31125423	RESULT	1	PubMed
31078463	RESULT	1	PubMed
30217671	RESULT	1	PubMed

1 to 10 of 197

See all 197 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018078

GET https://conductscience.org/api/diseases/v1/MONDO_0018078/drugs?page=2

API reference For AI assistants